Inventor · disambiguated record
Mohammed I. Dibas
Also filed as: DIBAS MOHAMMED · DIBAS MOHAMMED I
16 granted patents·40 pending applications·40 citations·filing 2009–2024
91Inventor score
Top patents by PatentIndex Score
56 records- 0195US11077053B2Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopiaALLERGAN INC·Filed 2020·Granted Aug 3, 2021·4 cites·11 claims
- 0294US11285134B2Presbyopia treatmentsALLERGAN INC·Filed 2020·Granted Mar 29, 2022·5 cites·36 claims
- 0393US10610518B2Presbyopia treatmentsALLERGAN INC·Filed 2019·Granted Apr 7, 2020·17 cites·20 claims
- 0490US9283217B2Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2013·Granted Mar 15, 2016·6 cites·4 claims
- 0589US2025375423A1Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseasesALLERGAN INC·Filed 2024·Application pending·0 cites
- 0689US2025228823A1Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanolALLERGAN INC·Filed 2024·Application pending·0 cites
- 0785US8853251B2Ester pro-drugs of [3-(1-(1H-imidazol-4-YL)ethyl)-2-methylphenyl] methanol for treating retinal diseasesALLERGAN INC·Filed 2013·Granted Oct 7, 2014·4 cites·7 claims
- 0883US9095576B2Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseasesALLERGAN INC·Filed 2012·Granted Aug 4, 2015·3 cites·1 claims
- 0983US2024358682A1Use of alpha-2-adrenergic receptor agonists for improving visionALLERGAN INC·Filed 2024·Application pending·0 cites
- 1081US2022233505A1Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseasesALLERGAN INC·Filed 2022·Application pending·0 cites
- 1180US10555933B2Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseasesALLERGAN INC·Filed 2018·Granted Feb 11, 2020·1 cites·2 claims
- 1280US2024382462A1Presbyopia treatmentsALLERGAN INC·Filed 2024·Application pending·0 cites
- 1379US2024390330A1Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposesALLERGAN INC·Filed 2024·Application pending·0 cites
- 1477US2024173300A1Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposesALLERGAN INC·Filed 2023·Application pending·0 cites
- 1576US2020206193A1Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanolALLERGAN INC·Filed 2019·Application pending·0 cites
- 1675US2022008393A1Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanolALLERGAN INC·Filed 2021·Application pending·0 cites
- 1773US11331306B2Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseasesALLERGAN INC·Filed 2020·Granted May 17, 2022·0 cites·12 claims
- 1873US2022288031A1Alpha-2-adrenergic receptor agonists for improving visionALLERGAN INC·Filed 2021·Application pending·0 cites
- 1973US2022241245A1Presbyopia treatmentsALLERGAN INC·Filed 2022·Application pending·0 cites
- 2072US2024335425A1Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving visionALLERGAN INC·Filed 2024·Application pending·0 cites
- 2172US2022160623A1Use of alpha-2-adrenergic receptor agonists for improving visionALLERGAN INC·Filed 2021·Application pending·0 cites
- 2266US10201535B2Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2017·Granted Feb 12, 2019·0 cites·17 claims
- 2366US2021260042A1Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposesALLERGAN INC·Filed 2021·Application pending·0 cites
- 2465US2013289088A1Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressureALLERGAN INC·Filed 2013·Application pending·0 cites
- 2565US2013296394A1Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditionsALLERGAN INC·Filed 2013·Application pending·0 cites
- 2663US2016354346A1Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditionsALLERGAN INC·Filed 2016·Application pending·0 cites
- 2762US9199989B2N—(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptorsALLERGAN INC·Filed 2014·Granted Dec 1, 2015·0 cites·9 claims
- 2862US2021205273A1The use of alpha-2-adrenergic receptor agonists for improving visionALLERGAN INC·Filed 2019·Application pending·0 cites
- 2961US9034896B2N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptorsALLERGAN INC·Filed 2014·Granted May 19, 2015·0 cites·9 claims
- 3061US2016303083A1Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3himidazole derivatives for treating retinal diseasesALLERGAN INC·Filed 2016·Application pending·0 cites
- 3161US2017172983A1Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanolALLERGAN INC·Filed 2017·Application pending·0 cites
- 3260US8741921B2N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptorsALLERGAN INC·Filed 2013·Granted Jun 3, 2014·0 cites·9 claims
- 3359US8815861B2N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptorsSINHA SANTOSH C·Filed 2012·Granted Aug 26, 2014·0 cites·12 claims
- 3459US8513419B2N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptorsSINHA SANTOSH C·Filed 2012·Granted Aug 20, 2013·0 cites·11 claims
- 3559US2015148394A1Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditionsALLERGAN INC·Filed 2015·Application pending·0 cites
- 3658US2015250764A1Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3himidazole derivatives for treating retinal diseasesALLERGAN INC·Filed 2015·Application pending·0 cites
- 3758US2016151349A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2016·Application pending·0 cites
- 3858US2021260041A1Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving visionALLERGAN INC·Filed 2021·Application pending·0 cites
- 3958US2016067222A1Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanolALLERGAN INC·Filed 2015·Application pending·0 cites
- 4057US2013123303A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2012·Application pending·0 cites
- 4155US9308201B2Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2015·Granted Apr 12, 2016·0 cites·7 claims
- 4255US2017095466A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2016·Application pending·0 cites
- 4353US2022273605A1Compositions and methods for treatment of presbyopiaALLERGAN INC·Filed 2020·Application pending·0 cites
- 4453US2014235685A1Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseasesALLERGAN INC·Filed 2014·Application pending·0 cites
- 4552US2016051534A1Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8- tetrahydro-quinoline for treating skin diseases and conditionsALLERGAN INC·Filed 2015·Application pending·0 cites
- 4651US2013210876A1Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effectALLERGAN INC·Filed 2013·Application pending·0 cites
- 4751US2011009453A1s1p3 receptor inhibitors for treating inflammationDONELLO JOHN E·Filed 2009·Application pending·0 cites
- 4849US2022273557A1Compositions and methods for treatment of presbyopiaALLERGAN SALES LLC·Filed 2020·Application pending·0 cites
- 4949US2016045489A1N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptorsALLERGAN INC·Filed 2015·Application pending·0 cites
- 5045US2014275197A1Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routesALLERGAN INC·Filed 2014·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mohammed I. Dibas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →